STOCK TITAN
  1. Home
  2. News
  3. RYZB

RayzeBio, Inc. - $RYZB STOCK NEWS

Welcome to our dedicated page for RayzeBio news (Ticker: $RYZB), a resource for investors and traders seeking the latest updates and insights on RayzeBio stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RayzeBio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RayzeBio's position in the market.

News
Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform
Rhea-AI Summary
Bristol Myers Squibb (BMY) completes the acquisition of RayzeBio, Inc. (RYZB) to strengthen its oncology pipeline with radiopharmaceutical therapeutics. The acquisition includes RYZ101, a promising RPT targeting somatostatin receptor 2 in GEP-NETs and ES-SCLC. Bristol Myers Squibb plans to leverage RayzeBio's IND engine and manufacturing facility to accelerate preclinical and clinical programs, offering growth opportunities in the coming years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
acquisition
-
News
Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer
Rhea-AI Summary
Bristol Myers Squibb (BMY) has completed the acquisition of RayzeBio, Inc. for approximately $4.1 billion, with 86% of RayzeBio's shares tendered. The transaction is expected to close on February 26, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
none
-
News
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
Rhea-AI Summary
Bristol Myers Squibb (BMY) and RayzeBio, Inc. (RYZB) announce the expiration of the waiting period under the HSR Act for BMY's tender offer to acquire RYZB for $62.50 per share in cash, totaling $4.1 billion. The transaction remains subject to the tender of a majority of RYZB's outstanding shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
none
News
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
Rhea-AI Summary
Bristol Myers Squibb (BMY) to Acquire RayzeBio (RYZB) for $4.1 Billion, Expanding Oncology Portfolio and Radiopharmaceutical Platform
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
acquisition
-
News
RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
RayzeBio, Inc. (Nasdaq: RYZB) reported financial results for Q3 2023 and provided updates on clinical trials and corporate milestones. Recent highlights include RYZ101's Phase 3 clinical trial progress and a confirmed objective response rate of 29%. RYZ801 and RYZ811 IND filing for HCC is expected in 1H 2024. The company's manufacturing facility is on track for completion by the end of 2023, and it completed a $357 million IPO. The cash position as of September 30, 2023, was $540.2 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.99%
Tags
earnings
-
News
RayzeBio to Participate in Upcoming Investor Conferences in November 2023
Rhea-AI Summary
RayzeBio, Inc. (Nasdaq: RYZB) will be participating in several investor conferences in November 2023 to discuss their innovative radiopharmaceutical pipeline for cancer treatment. The conferences include Truist Securities BioPharma Symposium, Jefferies London Healthcare Conference, and Evercore ISI HealthCONx Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
conferences
News
RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors
Rhea-AI Summary
RayzeBio, Inc. has announced the appointment of Tim Van Hauwermeiren to its board of directors. Tim, the co-founder and CEO of argenx, brings extensive experience in general management and business development. RayzeBio aims to transform the oncology treatment landscape through targeted radiopharmaceuticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.81%
Tags
management
-
News
FDA selects RayzeBio to Participate in the Inaugural CDRP Program to Expedite Commercial Manufacturing Readiness for RYZ101 in GEP-NETs
Rhea-AI Summary
RayzeBio's RYZ101 selected by FDA for CMC Development and Readiness Pilot program
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
conferences
-
News
RayzeBio to Present at European Society for Medical Oncology (ESMO) Congress
Rhea-AI Summary
RayzeBio to present interim safety and efficacy data from Phase 1b trial at ESMO Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
conferences
News
RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Rhea-AI Summary
RayzeBio, Inc. closes upsized $358 million IPO, selling 19,869,240 shares of common stock at $18.00 per share. Gross proceeds to RayzeBio were approximately $336.7 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
IPO offering
Stock RYZB logo
RayzeBio, Inc.

NYSE:RYZB

RYZB Rankings

N/A Ranked by Market Cap
#1852 Ranked by Stock Gains
N/A Ranked by Dividends

RYZB Stock Data

3.75B
34.82M
9.69%
89.71%
1.41%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
San Diego